{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:02Z","timestamp":1791105662006,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":354,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>The safety of entacapone combined with levodopa and a dopadecarboxylase (DDC) inhibitor was tested in a 12\u2010month double\u2010blind study of 326 patients with idiopathic Parkinson\u2019s disease (PD). The study population represented \u2018typical\u2019 PD outpatients, including patients with varying disease severity and with various concomitant medications. Two\u2010thirds of the patients were randomized to receive 200\u2003mg of entacapone with each of 2\u201310 daily levodopa doses, and one\u2010third to receive placebo. All entacapone patients were included in the safety evaluation of adverse events (AEs), vital signs, ECG, and laboratory parameters. Entacapone was well tolerated with a discontinuation rate due to AEs of 14% compared with 11% with placebo (NS). As expected, due to dopaminergic enhancement, dyskinesia was more frequent as an AE with entacapone than with placebo. Dryness of mouth, urine discoloration and diarrhoea were more frequent non\u2010dopaminergic AEs with entacapone than with placebo. Entacapone had no adverse effects on hepatic enzyme activity, ECG or haemodynamic parameters, and there was no evidence of any toxicity. As an indication of levodopa enhancement with entacapone, patients taking 5\u201310 doses of levodopa, most likely representing predominantly fluctuating patients, showed a significant decrease in their mean daily levodopa dose of 94\u2003mg in the entacapone group compared with a decrease of 39\u2003mg in the placebo group (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). The interval between the first two morning doses of levodopa increased by 17% with entacapone, whereas with placebo no extension was observed (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Despite levodopa dose reduction, efficacy of entacapone was maintained. As further evidence of efficacy, Parkinsonian symptoms markedly worsened in all patients after withdrawal of entacapone. We conclude that entacapone is safe in optimizing levodopa in long\u2010term treatment of idiopathic Parkinson\u2019s disease. Monitoring of liver or other safety parameters during entacapone treatment is not required.<\/jats:p>","DOI":"10.1046\/j.1468-1331.2001.00168.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T19:37:22Z","timestamp":1047411442000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Twelve\u2010month safety of entacapone in patients with Parkinson\u2019s disease"],"prefix":"10.1111","volume":"8","author":[{"given":"V. V.","family":"Myllyl\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.\u2010R.","family":"Kultalahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Haapaniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FILOMEN Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.4.421"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5_Suppl_5.S17"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196702162760703"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_5_6_1","first-page":"324","article-title":"Inhibition of catechol\u2010O\u2010methyltransferase activity with entacapone does not affect hemodynamics or plasma catecholamine levels during exercise.","volume":"42","author":"Gordin A","year":"1992","journal-title":"Neurology"},{"key":"e_1_2_5_7_1","first-page":"135","article-title":"Catechol\u2010O\u2010methyl transferase: pharmacological aspects and physiological role.","volume":"27","author":"Guldberg HC","year":"1975","journal-title":"Pharmacol Rev"},{"key":"e_1_2_5_8_1","first-page":"41","volume-title":"Mov Disord","author":"Hornykiewicz O","year":"1982"},{"key":"e_1_2_5_9_1","first-page":"582","article-title":"COMT inhibition by high\u2010dose entacapone changes catecholamine metabolism in healthy volunteers at rest and during exercise.","volume":"32","author":"Illi A","year":"1994","journal-title":"Int J Clin Pharmacol Therapeutics"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.1.77"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199304000-00007"},{"key":"e_1_2_5_12_1","first-page":"333","article-title":"Catecholamine metabolism: basic aspects and clinical significance.","volume":"37","author":"Kopin IJ","year":"1985","journal-title":"Pharmacol Rev"},{"key":"e_1_2_5_13_1","first-page":"453","article-title":"The neurochemistry of Parkinson\u2019s disease: effect of L\u2010Dopa therapy.","volume":"195","author":"Lloyd KG","year":"1975","journal-title":"J Pharmacol Exp Therapeut"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1990.tb00756.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.6.672"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.2.186"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315512"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.5.913"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420511"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1066"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.5.1309"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1983.tb01513.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199619030-00004"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00394.x"},{"key":"e_1_2_5_25_1","first-page":"S35","article-title":"New and emerging strategies for improving levodopa treatment.","volume":"44","author":"Tolosa ES","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.665"},{"key":"e_1_2_5_27_1","first-page":"S72","article-title":"Tolcapone increases plasma catecholamine levels in patients with PD.","volume":"5","author":"De Yebenes JG","year":"1999","journal-title":"Parkinsonism and Related Disorders"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-1331.2001.00168.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-1331.2001.00168.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T16:48:36Z","timestamp":1697647716000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1468-1331.2001.00168.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1468-1331.2001.00168.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1468-1331.2001.00168.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"2001-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}